CR20120524A - Combinaciones que contienen 2,3-dihidroimidazo [1,2-c] quinazolina sustituida - Google Patents

Combinaciones que contienen 2,3-dihidroimidazo [1,2-c] quinazolina sustituida

Info

Publication number
CR20120524A
CR20120524A CR20120524A CR20120524A CR20120524A CR 20120524 A CR20120524 A CR 20120524A CR 20120524 A CR20120524 A CR 20120524A CR 20120524 A CR20120524 A CR 20120524A CR 20120524 A CR20120524 A CR 20120524A
Authority
CR
Costa Rica
Prior art keywords
dihydroimidazo
quinazoline
replaced
combinations containing
solvate
Prior art date
Application number
CR20120524A
Other languages
English (en)
Spanish (es)
Inventor
Ningshu Liu
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44144895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120524(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CR20120524A publication Critical patent/CR20120524A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CR20120524A 2010-04-16 2012-10-16 Combinaciones que contienen 2,3-dihidroimidazo [1,2-c] quinazolina sustituida CR20120524A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10160109 2010-04-16

Publications (1)

Publication Number Publication Date
CR20120524A true CR20120524A (es) 2013-01-09

Family

ID=44144895

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120524A CR20120524A (es) 2010-04-16 2012-10-16 Combinaciones que contienen 2,3-dihidroimidazo [1,2-c] quinazolina sustituida

Country Status (24)

Country Link
US (1) US20130184270A1 (enExample)
EP (1) EP2558126A2 (enExample)
JP (1) JP5886271B2 (enExample)
KR (1) KR20130098155A (enExample)
CN (1) CN102958540B (enExample)
AU (1) AU2011240003A1 (enExample)
BR (1) BR112012026480A2 (enExample)
CA (1) CA2796253A1 (enExample)
CL (1) CL2012002887A1 (enExample)
CO (1) CO6620036A2 (enExample)
CR (1) CR20120524A (enExample)
CU (1) CU20120150A7 (enExample)
DO (1) DOP2012000269A (enExample)
EA (1) EA201201414A8 (enExample)
EC (1) ECSP12012261A (enExample)
IL (1) IL222356A0 (enExample)
MA (1) MA34158B1 (enExample)
MX (1) MX2012012064A (enExample)
PE (1) PE20130191A1 (enExample)
PH (1) PH12012502069A1 (enExample)
SG (1) SG184550A1 (enExample)
TN (1) TN2012000493A1 (enExample)
WO (1) WO2011128407A2 (enExample)
ZA (1) ZA201208616B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2014160034A1 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Aldehyde dehydrogenase-1 modulators and methods of use thereof
AP2015008750A0 (en) 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
EA201791974A1 (ru) * 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
WO2017153220A1 (en) * 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO2004029055A1 (en) * 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
DE102004064002B4 (de) 2004-08-04 2019-05-09 Continental Automotive Gmbh System zum Überwachen einer Sensorvorrichtung
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
MX2008002114A (es) * 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CN102131771A (zh) * 2008-04-14 2011-07-20 阿迪生物科学公司 组合物及其制备和使用方法
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Also Published As

Publication number Publication date
SG184550A1 (en) 2012-11-29
MX2012012064A (es) 2012-12-17
JP5886271B2 (ja) 2016-03-16
IL222356A0 (en) 2012-12-31
JP2013525293A (ja) 2013-06-20
EP2558126A2 (en) 2013-02-20
US20130184270A1 (en) 2013-07-18
DOP2012000269A (es) 2012-12-15
CO6620036A2 (es) 2013-02-15
CU20120150A7 (es) 2013-02-26
CL2012002887A1 (es) 2013-01-18
CN102958540B (zh) 2015-09-02
EA201201414A8 (ru) 2013-12-30
AU2011240003A1 (en) 2012-11-08
WO2011128407A3 (en) 2012-02-23
ZA201208616B (en) 2015-08-26
CA2796253A1 (en) 2011-10-20
CN102958540A (zh) 2013-03-06
PE20130191A1 (es) 2013-02-21
HK1182937A1 (en) 2013-12-13
WO2011128407A9 (en) 2011-12-22
BR112012026480A2 (pt) 2016-08-16
KR20130098155A (ko) 2013-09-04
WO2011128407A2 (en) 2011-10-20
ECSP12012261A (es) 2012-11-30
MA34158B1 (fr) 2013-04-03
TN2012000493A1 (en) 2014-04-01
EA201201414A1 (ru) 2013-04-30
PH12012502069A1 (en) 2013-02-04

Similar Documents

Publication Publication Date Title
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
ECSP10010722A (es) Compuestos orgánicos
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
MX2016006336A (es) Compuestos pirazolopirimidina.
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
EA201071329A1 (ru) Диамидные производные адамантана и их применение
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
CR20110370A (es) Derivados de sulfonamida
EA201490287A1 (ru) Новые замещенные производные индола в качестве модуляторов гамма-секретазы
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
CO6630154A2 (es) Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
CR20140294A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CY1118365T1 (el) Διαμορφωτες διυδροπυραζολης του gpr40
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
EA201490823A1 (ru) Агенты, реверсирующие действие антикоагулянтов
EA201600619A1 (ru) Хромен и 1,1а, 2,7в-тетрагидроциклопропа[с]хромен пиридопиразиндионы в качестве модулятора гамма-секретазы
BR112014008555A2 (pt) r(+)-n-formil-propargil-aminoindano
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
EA201290229A1 (ru) Производные спиролактама и их применение